Valion Bio Total Revenue

As of the most recent data (June 2026), VBIO shows a total revenue of $-160K. That compares with $460K in the prior-year period — down 133.8% year over year. That is below the sector sector average of $1.4B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VBIO's total revenue is now $-160K (was $460K) — a 133.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Valion Bio is outperforming or lagging.

The its sector sector average total revenue is about $1.4B. Valion Bio is at $-160K, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how VBIO stacks up against individual peers as well.

Tracking VBIO's total revenue over time shows whether Valion Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $-160K That compares with $460K in the prior-year period — down 133.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has Valion Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $-160K) with ownership activity and broader fundamentals.